FDA expands use of Actemra for earlier-stage arthritis


FDA has expanded the approved indication for tocilizumab (Actemra, Genentech) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.